Tavilermide (
INN) (developmental code name MIM-D3) is a
selective,
cyclic tripeptide partial agonist of
TrkA. (this class of drugs is sometimes referred to as
nerve growth factor
Nerve growth factor (NGF) is a neurotrophic factor and neuropeptide primarily involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It is perhaps the prototypical growth factor, in that it was on ...
(NGF)
mimetic
Mimesis (; grc, μίμησις, ''mīmēsis'') is a term used in literary criticism and philosophy that carries a wide range of meanings, including '' imitatio'', imitation, nonsensuous similarity, receptivity, representation, mimicry, the ...
s)
Tavilermide was first synthesized by Burgess and co-workers at Texas A&M University with the intention of producing TrkA agonists. It is under development by Mimetogen Pharmaceuticals as an
ophthalmic (eye drop) solution for the treatment of
dry eyes, and is in
phase III clinical trials for this indication. Tavilermide is currently being evaluated in two multi-center phase III clinical studies in the United States for the treatment of dry eye diseas
Tavilermide is also in
Phases of clinical research#Phase I, phase I clinical trials for the treatment of
glaucoma; studies are ongoing.
See also
*
Cenegermin
Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor (rhNGF), is a recombinant form of human nerve growth factor (NGF). In July 2017, it was approved in the European Union as an eye drop formulation ...
References
External links
Clinical Development - Mimetogen PharmaceuticalsTavilermide - AdisInsight
{{Growth factor receptor modulators
Glaucoma
Ophthalmology drugs
Receptor agonists
Cyclic peptides
Nitrobenzenes
Tripeptides